Acep Riza Wijayadikusumah

Dr. Acep Riza Wijayadikusumah

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
TTTarwadi Tarwadi
Tarwadi Tarwadi
SPSabar Pambudi
Sabar Pambudi
CSCatur Sriherwanto
Catur Sriherwanto
ASAyu N. Sasangka
Ayu N. Sasangka
Anom BowolaksonoAnom Bowolaksono
Anom Bowolaksono
Mohsin kaziMohsin kazi
Mohsin kazi

9 February 2026 in Fermentation
Verified
Journal Article
Open access
PDF file
AYAlmir Yamanie
Almir Yamanie
SMSalomé de Sá Magalhães
Salomé de Sá Magalhães
AWAcep Riza Wijayadikusumah
Acep Riza Wijayadikusumah
NNNeni Nurainy
Neni Nurainy
EKEli Keshavarz-Moore
Eli Keshavarz-Moore
The increasing demand for recombinant proteins has driven innovation in bioprocessing strategies using Komagataella phaffii as a host organism. Conventional fed-batch cultivation with pure methanol induction remains widely used but presents challenges including high methanol consumption, extended downtime, and elevated operational costs. This study evaluates alternative strategies combining mixed induction (methanol/sorbitol) with continuous cultivation to enhance productivity, sustainability, and improved economic outcome. Using KEX2 protease as a model industrial recombinant protein, we compared four cultivation modes: fed-batch with methanol (benchmark), fed-batch with mixed induction, continuous with methanol, and continuous with mixed induction. Cell growth, volumetric yield, and specific productivity were evaluated at 5L scale and then modelled to simulate industrial scales (40 L and 400 L). Results demonstrate that continuous cultivation with mixed induction significantly improves yield up to 9-fold compared to conventional fed-batch and reduces methanol usage and oxygen demand. Techno-economic simulations reveal that a 40 L continuous process can match or exceed the output of two 400 L fed-batch runs, while lowering capital and operating costs and minimizing environmental footprint. This integrated strategy offers a scalable, low-cost, and safer method for recombinant protein production, supporting compact and sustainable manufacturing solutions.

5 September 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
SMSalomé de Sá Magalhães
Salomé de Sá Magalhães
SMStephen A Morris
Stephen A Morris
SKShinta Kusumawardani
Shinta Kusumawardani
AWAcep Riza Wijayadikusumah
Acep Riza Wijayadikusumah
NNNeni Nurainy
Neni Nurainy
EKEli Keshavarz-Moore
Eli Keshavarz-Moore
Dengue is a rapidly spreading mosquito-borne viral infection, with increasing reports of outbreaks globally. According to the World Health Organization (WHO), by 30 April 2024, over 7.6 million dengue cases were reported, including 3.4 million confirmed cases, more than 16,000 severe cases, and over 3000 deaths. As dengue remains endemic in many regions, there is a critical need for the development of new vaccines and manufacturing processes that are efficient, cost-effective, and capable of meeting growing demand. In this study, we explore an alternative process development pathway for the future manufacturing of a dengue vaccine, utilizing Komagataella phaffii (Pichia pastoris) as the host organism, one of the most promising candidates for the expression of heterologous proteins in vaccine development. It combines the speed and ease of highly efficient prokaryotic platforms with some key capabilities of mammalian systems, making it ideal for scalable and cost-effective production. The key outcomes of our research include (i) demonstrating the versatility of the Komagataella phaffii platform in the production of dengue viral-like particles (VLPs); (ii) optimizing the culture process using Design of Experiments (DoE) approaches in small-scale bioreactors; (iii) developing a novel purification platform for enveloped VLPs (eVLPs), and (iv) establishing alternative biophysical characterization methods for the dengue vaccine prototype. These findings provide a promising foundation for efficient and scalable production of dengue vaccines, addressing both technical and operational challenges in vaccine manufacturing.

19 January 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
EPElisa D. Pratiwi
Elisa D. Pratiwi
TMTiza W. Mawaddah
Tiza W. Mawaddah
ASArif R. Sadjuri
Arif R. Sadjuri
DNDimas Tri Nugroho
Dimas Tri Nugroho
AHArip Hidayat
Arip Hidayat
CNChairul A. Nidom
Chairul A. Nidom
Background: Administering several separate childhood vaccines can reduce adherence to immunization schedules due to missed appointments and the burden of repeated injections. A hexavalent formulation targeting diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type B, and poliovirus offers a practical approach to improve compliance and streamline immunization. Methods: Toxicity testing was performed in Wistar rats and New Zealand White rabbits (60 rats and 30 rabbits). Animals were distributed into three groups: hexavalent vaccine + low-dose sIPV, hexavalent vaccine + high-dose sIPV, and control. Each animal received a 0.5 mL intramuscular injection at weeks 0, 4, 8, and 12. Clinical observations were conducted throughout the study. Serum samples were collected one day before each injection and at the endpoint, while liver tissue was collected at the endpoint. ALT and AST concentrations were analyzed using an automated analyzer, and hepatic morphology was evaluated microscopically. Results: No abnormal clinical signs related to vaccination were observed. ALT concentrations showed no significant differences (p > 0.05). AST differences (p < 0.05) were detected between the high-dose group and the control on day 27 in female rabbits and on day 83 in female rats; however, all values remained within normal physiological limits. Histopathological examination revealed no irreversible hepatic lesions, including hydropic degeneration, portal inflammation, focal necrosis, or connective tissue proliferation, and no significant differences were noted (p > 0.05). Conclusions: Repeated administration of the hexavalent vaccine candidate at low and high doses produced no toxicological effects in animal models, supporting its safety for further clinical development.

3 September 2026 in Narra J
Verified
Journal Article
Open access
PDF file
TMTiza Wuri Mawaddah
Tiza Wuri Mawaddah
EPElisa D. Pratiwi
Elisa D. Pratiwi
ASArif Rahman Sadjuri
Arif Rahman Sadjuri
DNDimas Tri Nugroho
Dimas Tri Nugroho
AHArip Hidayat
Arip Hidayat
CNChairul A. Nidom
Chairul A. Nidom
Hexavalent vaccines simplify childhood immunization by combining antigens against six diseases in a single formulation; however, the immunogenicity of each component must be evaluated. This study assessed poliovirus-specific immunoglobulin G (IgG) responses elicited by candidate hexavalent vaccines containing different doses of Sabin strain-derived inactivated poliovirus vaccine (sIPV). A preclinical study was conducted using 40 Wistar rats allocated to five groups: hexavalent vaccine containing low-, medium-, or high-dose sIPV; pentavalent vaccine combined with sIPV; or adjuvant control. Each group comprised four male and four female rats. The animals received primary immunization at week 0 and booster doses at weeks 4 and 8. Serotype-specific IgG titers were measured at weeks 0, 4, 8, and 12 using indirect enzyme-linked immunosorbent assay. Antibody responses were analyzed using repeated-measures analysis of variance. Titers against poliovirus serotypes 1, 2, and 3 were negligible at baseline and remained low at week 4. Marked responses were observed in all vaccinated groups at week 8, followed by lower titers at week 12. Significant between-group differences were detected at weeks 8 and 12 for serotype 1 (p<0.001 and p=0.010), serotype 2 (both p<0.001), and serotype 3 (both p=0.010). However, no consistent dose–response pattern was observed across serotypes, time points, or sexes. All animals survived and gained body weight during follow-up. The candidate hexavalent formulations elicited marked poliovirus-specific binding-IgG responses, supporting further preclinical evaluation using validated serological and serotype-specific neutralization assays.

16 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AYAlmir Yamanie
Almir Yamanie
SMSalomé de Sá Magalhães
Salomé de Sá Magalhães
AWAcep Riza Wijayadikusumah
Acep Riza Wijayadikusumah
NNNeni Nurainy
Neni Nurainy
EKEli Keshavarz-Moore
Eli Keshavarz-Moore
The increasing demand for recombinant proteins has driven innovation in bioprocessing strategies using Komagataella phaffii as a host organism. Conventional fed-batch cultivation with pure methanol induction remains widely used but presents challenges including high methanol consumption, extended downtime, and elevated operational costs. This study evaluates alternative strategies combining mixed induction (methanol/sorbitol) with continuous cultivation to enhance productivity, sustainability, and improved economic outcome. Using KEX2 protease as a model industrial recombinant protein, we compared four cultivation modes: fed-batch with methanol (benchmark), fed-batch with mixed induction, continuous with methanol, and continuous with mixed induction. Cell growth, volumetric yield, and specific productivity were evaluated at 5L scale and then modelled to simulate industrial scales (40 L and 400 L). Results demonstrate that continuous cultivation with mixed induction significantly improves yield up to 9-fold compared to conventional fed-batch and reduces methanol usage and oxygen demand. Techno-economic simulations reveal that a 40 L continuous process can match or exceed the output of two 400 L fed-batch runs, while lowering capital and operating costs and minimising environmental footprint. This integrated strategy offers a scalable, cost-effective, and safer alternative for recombinant protein production, supporting the development of compact and sustainable manufacturing platform.